Amgen Inc. (AMGN)
| Market Cap | 145.81B |
| Revenue (ttm) | 26.83B |
| Net Income (ttm) | 7.57B |
| Shares Out | 535.18M |
| EPS (ttm) | 14.07 |
| PE Ratio | 19.36 |
| Forward PE | 13.92 |
| Dividend | $8.52 (3.13%) |
| Ex-Dividend Date | Nov 16, 2023 |
| Volume | 1,541,228 |
| Open | 269.97 |
| Previous Close | 269.64 |
| Day's Range | 267.62 - 272.59 |
| 52-Week Range | 211.71 - 288.46 |
| Beta | 0.58 |
| Analysts | Buy |
| Price Target | 275.32 (+1.05%) |
| Earnings Date | Oct 31, 2023 |
About AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment o... [Read more]
Financial Performance
In 2022, Amgen's revenue was $26.32 billion, an increase of 1.32% compared to the previous year's $25.98 billion. Earnings were $6.55 billion, an increase of 11.18%.
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for AMGN stock is "Buy." The 12-month stock price forecast is $275.32, which is an increase of 1.05% from the latest price.
News
AMGEN TO PRESENT AT THE EVERCORE ISI HEALTHCONX CONFERENCE
THOUSAND OAKS, Calif. , Nov. 22, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Evercore ISI HealthCONx Conference at 9:10 a.m.
New ETF invested in Ozempic maker and exposed to other obesity drugs falls in first day of trade
A new ETF hit the market Tuesday, creating buzz for its exposure to popular weight-loss drugs, while expanding the roster of thematic ETFs available for investors willing to pay up for stock-picking p...
6 intriguing stocks investors should consider: Piper Sandler
The market has slightly rebounded, with some investors excited for a possible Santa Claus rally to close out the year. Piper Sandler's technical research team announced six stocks that are currently l...
AMGEN PRESENTS NEW CARDIOVASCULAR RESEARCH AT AHA 2023
New Repatha® (evolocumab) Data Show No Decline in Cognitive Function Associated With Very Low Levels of LDL-C Olpasiran Research Provides Further Insights Into Cardiovascular Risks Associated With Ele...
US Senator Elizabeth Warren expresses 'disappointment' in FTC's Amgen decision
Senator Elizabeth Warren, an antitrust hawk, expressed disappointment with the U.S. Federal Trade Commission's decision to allow pharmaceutical firm Amgen to move forward with its acquisition of Horiz...
AMGEN PRESENTS NEW RESEARCH IN EARLY PSORIATIC ARTHRITIS AT ACR 2023
FOREMOST Study Finds Oral Otezla ® (apremilast) Significantly Improved Disease Control vs. Placebo THOUSAND OAKS, Calif.
AMGEN PRESENTS NEW DATA FROM PHASE 2 TRIAL OF DAZODALIBEP IN SJÖGREN'S SYNDROME AT ACR 2023
First Phase 2 Trial in Sjögren's to Achieve the Primary Endpoint Both in Patients With Severe Symptomatology and Those With Systemic Disease Results From Crossover Period Provide Further Evidence of ...
Epidemiology and Genetics of Clonal Hematopoiesis, a Premalignant Hematopoietic Stem Cell Condition
Reykjavik, ICELAND , Nov. 6, 2023 /PRNewswire/ -- A comprehensive new study from deCODE genetics, a subsidiary of Amgen, published today in Nature Genetics, provides insights into the epidemiology and...
AMGEN PRESENTS NEW DATA THAT SHOW BLOOD PRESSURE DECREASES FOR ADULTS TREATED WITH KRYSTEXXA® (PEGLOTICASE)
THOUSAND OAKS, Calif. , Nov. 2, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data for KRYSTEXXA® (pegloticase) showing a decrease in blood pressure during treatment of adults living wi...
5 Dow stocks to track during the market correction
The Dow Jones Industrial Average of blue chip stocks is trading higher for the week, but is still in correction territory, having posted losses in each of the past three months.
AMGEN TO PRESENT DATA AT ACR 2023 ACROSS EXPANDED RHEUMATOLOGY PIPELINE AND PORTFOLIO
Breadth of Research Reflects Amgen's Commitment to Rheumatology Data Include Sjögren's Syndrome, Uncontrolled Gout, Severe Active ANCA-Associated Vasculitis and Psoriatic Arthritis THOUSAND OAKS, Cali...
Investor patience tested as pharmaceutical stocks take a tumble
The Health Care Select Sector SPDR Fund NYSEARCA: XLV was down 3.81% in the past month and 8.03% in the past three months. The latest round of pharmaceutical stock earnings isn't helping sector perfor...
Amgen gets FDA approval for its inflammatory diseases treatment Wezlana
Amgen AMGN, -2.85% has received approval from the U.S. Food and Drug Administration for Wezlana, its treatment for multiple inflammatory diseases.
U.S. FDA approves Amgen's biosimilar vesrion of J&J's Stelara
The U.S. Food and Drug Administration on Tuesday approved Amgen's biosimilar version of Johnson & Johnson's blockbuster psoriasis treatment Stelara for multiple inflammatory diseases.
Amgen's obesity drug plans, outlook for 2024
Amgen (AMGN) reported third-quarter earnings that beat expectations and raised its full-year revenue guidance. The company recently completed its acquisition of Horizon Therapeutics, which brings its ...
Amgen Boosts Revenue Guidance. But the Stock Trades Lower.
The biotechnology company beat third-quarter adjusted earnings estimates but fell a bit short on sales.
Amgen's stock jumps premarket after earnings beat and company again raises guidance
Amgen Inc.'s stock AMGN, +0.62% rose 2.9% in premarket trade Tuesday, after the biotech blew past earnings estimates for the third quarter and again raised its guidance. The company posted net income ...
Amgen third-quarter sales rise 5%; profit up before charge
Amgen , which earlier this month acquired Horizon Therapeutics for $27.8 billion, on Tuesday said its third-quarter product sales rose 5% as double-digit volume growth was offset by lower prices.
AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS
THOUSAND OAKS, Calif. , Oct. 31, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 20231.
AMGEN ANNOUNCES WEBCAST OF 2023 THIRD QUARTER FINANCIAL RESULTS
THOUSAND OAKS, Calif. , Oct. 25, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Tuesday, October 31, 2023, before the opening of th...
AMGEN ANNOUNCES 2023 FOURTH QUARTER DIVIDEND
THOUSAND OAKS, Calif. , Oct. 24, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the fourth quarter of 2023.
AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS VECTIBIX® (PANITUMUMAB) DATA IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
First Global Phase 3 Study in Patients with Chemorefractory KRAS G12C - Mutated Metastatic Colorectal Cancer Results Featured in a Presidential Symposium at ESMO and Simultaneously Published in the Ne...
AMGEN PRESENTS NEW TARLATAMAB DATA IN SMALL CELL LUNG CANCER
Tarlatamab Delivered an Encouraging Objective Response Rate of 40% and Median Overall Survival of 14.3 Months in Patients with Advanced SCLC Late-Breaking Data Presented at ESMO and Published in the N...